Mimetogen Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Novel NGF Mimetic In Patients With Dry Eye
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease...